Organization | SmartPractice

SmartPractice Report issue

Contributed to NME For profit Phase 2

Founded: Phoenix AZ United States (1969)

Status: Left NME R&D (2015)

Organization Overview

First Clinical Trial

2005

NCT00133341

First Marketed Drug

1997

thin-layer rapid use epicutaneous patch test (T.R.U.E. Test)

First NDA Approval

1997

thin-layer rapid use epicutaneous patch test (T.R.U.E. Test)

Last Known Activity

2005

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Mekos Laboratories AS | SmartPractice Denmark ApS

Active Ingredients

Marketed Drugs (1)

thin-layer rapid use epicutaneous patch test (T.R.U.E. Test) (1997 NDA)

Drugs in Phase 2 Trials (4)

aurothiosulfate (1 trial)

bacitracin (polysporin) (1 trial)

methyldibromoglutharonitrile (1 trial)

parthenolide (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Dermatitis (Phase 2)

Dermatitis, Allergic Contact (Phase 2)

Dermatitis, Contact (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 2
# of Trial APIs: 4